Order by: Title Ascending Title Descending Recent First Oldest First
Published on 22 November 2023 By ESCP Secretariat In AIN and Anal Cancer
Consultants corner - Raminta Luksaite Lukste (Lithuania) at ESCP Vilnius 2023
Published on 21 November 2023 By ESCP Secretariat In AIN and Anal Cancer
Education session - Sarah MIlls (United Kingdom) at ESCP Vilnius 2023
Published on 04 November 2019 By ESCP Secretariat In AIN and Anal Cancer
Symposium - Andreas Salat (Austria) at ESCP Vienna 2019
Symposium - Marianne G. Guren (Norway) at ESCP Vienna 2019
Educational session - Carlo Ratto (Italy) at ESCP Vienna 2019
Published on 13 November 2017 By ESCP Secretariat In AIN and Anal Cancer
ASCRS Visiting Fellow Free Paper - Brooks Rademacher at ESCP Berlin 2017
Published on 18 May 2017 By European Manual of Medicine: Coloproctology In AIN and Anal Cancer
Within the past few decades the incidence of anal cancer has increased worldwide, especially among the male homosexual population (men who have sex with men [MSM]), with an incidence up to 225 in 100,000. Human papillomavirus (HPV) infections are a main risk factor for the occurrence of anal cancer. The prevalence of anal HPV infection in human immunodeficiency virus (HIV)–negative MSM is 50–60 %, whereas the prevalence reaches almost 100 % in HIV-positive MSM. Anal intraepithelial neoplasia (AIN), which is associated with HPV, has been identified as a precursor lesion for anal cancer. Approximately 20 % of HIV-negative MSM are diagnosed with AIN, and high-grade epithelial neoplasia is already present in 5–10 %. The prevalence of high-grade AIN among HIV-positive MSM is considerably higher and can reach 50 %. In hypothetical models, screening examinations such as anal cytology and high-resolution anoscopy have been shown to be cost-effective and efficient in MSM. Based on these findings, regular anal screening tests should be recommended for at-risk patients. If anal cancer is diagnosed, positron emission tomography/computed tomography is recommended for staging. Radiochemotherapy is the standard treatment for most patients. Surgery is only advisable in patients with small tumors (<2 cm) of the anal margin or as a salvage procedure. Follow-up should be performed for 3 years and should include digital rectal examination and palpation of inguinal lymph nodes.
Published on 03 November 2016 By ESCP Secretariat In AIN and Anal Cancer
Educational session - Daniel Dindo at ESCP Milan 2016
Published on 25 November 2015 By ESCP Secretariat In AIN and Anal Cancer
Symposium - Daniel Dindo at ESCP Dublin 2015
Symposium - Marianna Berho at ESCP Dublin 2015
Symposium - Evgeny Rybakov at ESCP Dublin 2015
Published on 12 December 2014 By ESCP Secretariat In AIN and Anal Cancer
Oral Poster (Neoplasia) - Maziar Nikberg at ESCP Barcelona 2014
Published on 07 August 2014 By ESCP Secretariat In AIN and Anal Cancer
CSSANZ Travelling Fellow visiting paper - Maria-Pia Bernardi (Australia) at Tripartite Colorectal Meeting 2014
Video Presentation - Guillermo Rosato (Argentina) at Tripartite Colorectal Meeting 2014
Published on 06 August 2014 By ESCP Secretariat In AIN and Anal Cancer
Short Paper - Maria-Pia Bernardi (Australia) at Tripartite Colorectal Meeting 2014
Short Paper - Zainul Abedin Kapacee (UK) at Tripartite Colorectal Meeting 2014
Short Paper - Sanjaya Wijeyekoon (UK) at Tripartite Colorectal Meeting 2014
Published on 04 November 2013 By ESCP Secretariat In AIN and Anal Cancer
Free paper - Laurent Siproudhis at ESCP Belgrade 2013
Oral poster - Jan Lee at ESCP Belgrade 2013
Published on 15 October 2012 By ESCP Secretariat In AIN and Anal Cancer
Symposium - Per J. Nilsson at ESCP Vienna 2012
Published on 18 October 2010 By ESCP Secretariat In AIN and Anal Cancer
Oral poster - Massimiliano Mistrangelo at ESCP Sorrento 2010
This site uses cookies to store information on your computer. Read more...
